Literature DB >> 21916992

Management of ascites in cirrhosis.

Florence Wong1.   

Abstract

Ascites is a common complication of liver cirrhosis associated with a poor prognosis. The treatment of ascites requires dietary sodium restriction and the judicious use of distal and loop diuretics, sequential at an earlier stage of ascites, and a combination at a later stage of ascites. The diagnosis of refractory ascites requires the demonstration of diuretic non-responsiveness, despite dietary sodium restriction, or the presence of diuretic-related complications. Patients with refractory ascites require second-line treatments of repeat large-volume paracentesis (LVP) or the insertion of a transjugular intrahepatic portosystemic shunt (TIPS), and assessment for liver transplantation. Careful patient selection is paramount for TIPS to be successful as a treatment for ascites. Patients not suitable for TIPS insertion should receive LVP. The use of albumin as a volume expander is recommended for LVP of >5-6 L to prevent the development of circulatory dysfunction, although the clinical significance of post-paracentesis circulatory dysfunction is still debated. Significant mortality is still being observed in cirrhotic patients with ascites and relatively preserved liver and renal function, as indicated by a lower Model for End-Stage Liver Disease (MELD) score. It is proposed that patients with lower MELD scores and ascites should receive additional points in calculating their priority for liver transplantation. Potential new treatment options for ascites include the use of various vasoconstrictors, vasopressin V(2) receptor antagonists, or the insertion of a peritoneo-vesical shunt, all of which could possibly improve the management of ascites.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21916992     DOI: 10.1111/j.1440-1746.2011.06925.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  19 in total

1.  Ascites in patients with cirrhosis.

Authors:  Giulia-Anna Perri
Journal:  Can Fam Physician       Date:  2013-12       Impact factor: 3.275

2.  Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.

Authors:  Ai Nakagawa; Masanori Atsukawa; Akihito Tsubota; Chisa Kondo; Tomomi Okubo; Taeang Arai; Norio Itokawa; Yoshiyuki Narahara; Katsuhiko Iwakiri
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

3.  Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.

Authors:  Tomoharu Yamada; Takamasa Ohki; Yuki Hayata; Yuki Karasawa; Satoshi Kawamura; Daisaku Ito; Kentaro Kojima; Michiharu Seki; Nobuo Toda; Kazumi Tagawa
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

Review 4.  The evolving concept of acute kidney injury in patients with cirrhosis.

Authors:  Florence Wong
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

5.  The future developments in hepatology: no need for a jaundiced view.

Authors:  Ahmed Mohamed Elsharkawy; Mark Hudson
Journal:  Frontline Gastroenterol       Date:  2012-05-31

Review 6.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  The Importance of Liver-Fatty Acid Binding Protein in Diagnosis of Liver Damage in Patients with Acute Hepatitis.

Authors:  Ozlem Ozer Cakir; Aysun Toker; Huseyin Ataseven; Ali Demir; Hakki Polat
Journal:  J Clin Diagn Res       Date:  2017-04-01

8.  Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.

Authors:  Hiang Keat Tan; Paul Damien James; Florence Wong
Journal:  Dig Dis Sci       Date:  2016-04-05       Impact factor: 3.199

Review 9.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

10.  Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

Authors:  Sheng-Hung Chen; Yu-Fen Li; Hsueh-Chou Lai; Jung-Ta Kao; Cheng-Yuan Peng; Po-Heng Chuang; Wen-Pang Su; I-Ping Chiang
Journal:  BMC Gastroenterol       Date:  2012-08-10       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.